Business Description
TransMedics Group Inc
NAICS : 334510
SIC : 3845
ISIN : US89377M1099
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.77 | |||||
Equity-to-Asset | 0.19 | |||||
Debt-to-Equity | 3.76 | |||||
Debt-to-EBITDA | -66.98 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.07 | |||||
Beneish M-Score | 2.91 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 92.7 | |||||
3-Year EBITDA Growth Rate | 36.8 | |||||
3-Year EPS without NRI Growth Rate | 12.4 | |||||
3-Year FCF Growth Rate | -68.1 | |||||
3-Year Book Growth Rate | 3.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 38.38 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.45 | |||||
9-Day RSI | 52.87 | |||||
14-Day RSI | 54.73 | |||||
6-1 Month Momentum % | 75.78 | |||||
12-1 Month Momentum % | 4.17 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.3 | |||||
Quick Ratio | 8.49 | |||||
Cash Ratio | 7.19 | |||||
Days Inventory | 132.36 | |||||
Days Sales Outstanding | 71.9 | |||||
Days Payable | 33.57 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.3 | |||||
Shareholder Yield % | -12.11 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 63.77 | |||||
Operating Margin % | -11.89 | |||||
Net Margin % | -10.36 | |||||
FCF Margin % | -79.5 | |||||
ROE % | -15.86 | |||||
ROA % | -4.72 | |||||
ROIC % | -19.97 | |||||
ROC (Joel Greenblatt) % | -12.45 | |||||
ROCE % | -3.23 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 229.71 | |||||
PS Ratio | 11.58 | |||||
PB Ratio | 20.04 | |||||
Price-to-Tangible-Book | 22.38 | |||||
EV-to-EBIT | -189.12 | |||||
EV-to-EBITDA | -389.87 | |||||
EV-to-Revenue | 12.43 | |||||
EV-to-Forward-Revenue | 8.1 | |||||
EV-to-FCF | -15.55 | |||||
Earnings Yield (Greenblatt) % | -0.53 | |||||
FCF Yield % | -6.95 |